# Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.

> **NCT01996319** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 194 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** QVA149
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01996319
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2016-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01996319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01996319, "Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01996319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*